PMID- 17573090
OWN - NLM
STAT- MEDLINE
DCOM- 20071108
LR  - 20071115
IS  - 0042-6822 (Print)
IS  - 0042-6822 (Linking)
VI  - 367
IP  - 1
DP  - 2007 Oct 10
TI  - Clinical and virological significance of the co-existence of HBsAg and anti-HBs 
      antibodies in hepatitis B chronic carriers.
PG  - 30-40
AB  - The co-existence of hepatitis B surface antigen (HBsAg) and anti-HBs antibodies 
      (HBsAb) in serum of hepatitis B virus (HBV)-chronic carriers has been previously 
      associated with HBsAg-amino acid (aa) substitutions. However, the aa pattern of 
      HBV-reverse transcriptase (RT) and the clinical settings associated with this 
      serological profile remain largely unknown. We studied thirteen 
      HBsAg-positive/HBsAb-positive patients. Newly diagnosed 
      HBsAg-positive/HBsAb-negative patients (n=51) served as controls. HBsAg/RT 
      sequences were obtained using in-house protocols. HBsAg-positive/HBsAb-positive 
      patients were predominantly immunosuppressed (69%). Five presented advanced liver 
      fibrosis. HBV DNA >5.0 log(10) copies/ml was significantly more frequent than in 
      controls. A significantly higher aa variability was observed versus controls 
      within HBsAg major hydrophilic region (MHR), especially the a-determinant, and 
      within RT for regions overlapping the MHR, the a-determinant, and HBsAg C 
      terminal region where drug resistance mutations occur. Further studies are needed 
      to determine whether this higher HBsAg/HBV-RT variability might favor 
      dissemination of anti-HBsAb escape HBV mutants and concomitantly alter 
      nucleos(t)ide analogs efficacy.
FAU - Colson, Philippe
AU  - Colson P
AD  - Laboratoire de Virologie, Federation Hospitaliere de Bacteriologie-Virologie 
      Clinique et d'Hygiene, Centre Hospitalier Universitaire Timone, 264 rue 
      Saint-Pierre 13385, Marseille Cedex 05, France. philippe.colson@ap-hm.fr
FAU - Borentain, Patrick
AU  - Borentain P
FAU - Motte, Anne
AU  - Motte A
FAU - Henry, Mireille
AU  - Henry M
FAU - Moal, Valerie
AU  - Moal V
FAU - Botta-Fridlund, Danielle
AU  - Botta-Fridlund D
FAU - Tamalet, Catherine
AU  - Tamalet C
FAU - Gerolami, Rene
AU  - Gerolami R
LA  - eng
PT  - Journal Article
DEP - 20070618
PL  - United States
TA  - Virology
JT  - Virology
JID - 0110674
RN  - 0 (Hepatitis B Antibodies)
RN  - 0 (Hepatitis B Surface Antigens)
RN  - EC 2.7.7.49 (HIV Reverse Transcriptase)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Amino Acid Substitution
MH  - *Carrier State/epidemiology/immunology/physiopathology/virology
MH  - Female
MH  - France/epidemiology
MH  - Genotype
MH  - HIV Reverse Transcriptase/genetics
MH  - Hepatitis B Antibodies/*blood
MH  - Hepatitis B Surface Antigens/*blood
MH  - Hepatitis B virus/genetics/immunology/*isolation & purification
MH  - *Hepatitis B, Chronic/epidemiology/immunology/physiopathology/virology
MH  - Hospitals, Public
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Prevalence
EDAT- 2007/06/19 09:00
MHDA- 2007/11/09 09:00
CRDT- 2007/06/19 09:00
PHST- 2007/01/24 00:00 [received]
PHST- 2007/05/04 00:00 [revised]
PHST- 2007/05/09 00:00 [accepted]
PHST- 2007/06/19 09:00 [pubmed]
PHST- 2007/11/09 09:00 [medline]
PHST- 2007/06/19 09:00 [entrez]
AID - S0042-6822(07)00356-X [pii]
AID - 10.1016/j.virol.2007.05.012 [doi]
PST - ppublish
SO  - Virology. 2007 Oct 10;367(1):30-40. doi: 10.1016/j.virol.2007.05.012. Epub 2007 
      Jun 18.